Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

37.62
-0.6300-1.65%
Pre-market: 37.39-0.2300-0.61%05:00 EDT
Volume:1.32M
Turnover:49.84M
Market Cap:3.25B
PE:-8.67
High:38.49
Open:37.88
Low:37.33
Close:38.25
Loading ...

Institutional investors may adopt severe steps after CRISPR Therapeutics AG's (NASDAQ:CRSP) latest 8.3% drop adds to a year losses

Simply Wall St.
·
25 Dec 2024

Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term

Zacks
·
23 Dec 2024

This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?

Motley Fool
·
23 Dec 2024

CRISPR Therapeutics: Promising Developments and Positive Outlook Amid Advancements in Gene-Editing

TIPRANKS
·
21 Dec 2024

Intellia Crashes 60% in a Year: How Should You Play the Stock?

Zacks
·
21 Dec 2024

3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025

Zacks
·
17 Dec 2024

2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?

Motley Fool
·
17 Dec 2024

Crispr Therapeutics call volume above normal and directionally bullish

TIPRANKS
·
17 Dec 2024

Stock Market Today: Dow Jones Up As Bitcoin Play Pops; Cathie Wood Loads Up On This AI Stock Amid 48% Plunge

Blockhead
·
17 Dec 2024

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory

Insider Monkey
·
15 Dec 2024

3 Things You Need to Know if You Buy CRISPR Therapeutics Today

Motley Fool
·
14 Dec 2024

2 Growth ETFs to Buy With $200 and Hold Forever

Motley Fool
·
13 Dec 2024

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

GlobeNewswire
·
13 Dec 2024

Is CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers?

Insider Monkey
·
12 Dec 2024

Catherine Wood's Strategic Acquisition of CRISPR Therapeutics AG Shares

GuruFocus
·
11 Dec 2024

Analysts Are Bullish on Top Healthcare Stocks: Crispr Therapeutics AG (CRSP), Silence Therapeutics (SLN)

TIPRANKS
·
10 Dec 2024

Crispr Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
10 Dec 2024

CRISPR Therapeutics Says Trial Data Show CTX112 Has 'Potential' to Treat Malignancies

MT Newswires Live
·
10 Dec 2024

Crispr Therapeutics presents data on CTX112 at ASH Meeting

TIPRANKS
·
10 Dec 2024

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

GlobeNewswire
·
10 Dec 2024